[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2173044A1 - Glycine, n-[n-l-gamma-glutamyl-3-(nitrosothio)-l-valyl] and use thereof - Google Patents

Glycine, n-[n-l-gamma-glutamyl-3-(nitrosothio)-l-valyl] and use thereof

Info

Publication number
ES2173044A1
ES2173044A1 ES200100577A ES200100577A ES2173044A1 ES 2173044 A1 ES2173044 A1 ES 2173044A1 ES 200100577 A ES200100577 A ES 200100577A ES 200100577 A ES200100577 A ES 200100577A ES 2173044 A1 ES2173044 A1 ES 2173044A1
Authority
ES
Spain
Prior art keywords
nitrosothio
valyl
glutamyl
glycine
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200100577A
Other languages
Spanish (es)
Other versions
ES2173044B1 (en
Inventor
Moliner Jose Repolles
Perez-Rasilla Eduardo Salas
Coy Francisco Pubill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lacer SA
Original Assignee
Lacer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lacer SA filed Critical Lacer SA
Priority to ES200100577A priority Critical patent/ES2173044B1/en
Priority to PCT/EP2002/002598 priority patent/WO2002085847A2/en
Priority to AU2002310939A priority patent/AU2002310939A1/en
Priority to PE2002000189A priority patent/PE20021040A1/en
Priority to PA20028541201A priority patent/PA8541201A1/en
Publication of ES2173044A1 publication Critical patent/ES2173044A1/en
Application granted granted Critical
Publication of ES2173044B1 publication Critical patent/ES2173044B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to glycine, N-[N-L-gamma-glutamyl-3-(nitrosothio)-L-valyl] having the following formula (I) (see formula I in paper form) and pharmaceutically acceptable salts thereof as well as pharmaceutical compositions comprising one or more of these compounds, methods for the treatment and prevention of diseases comprising administration of an effective amount of one or more of these compounds and the use of one or more or these compounds for the manufacture of a pharmaceutical composition for the treatment and prevention of diseases.
ES200100577A 2001-03-13 2001-03-13 DERIVATIVES OF GLYCINE, N- (N-L-GAMMA-GLUTAMIL-3- (NITROSOTIO) -L-VALIL) AND ITS APPLICATIONS. Expired - Fee Related ES2173044B1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES200100577A ES2173044B1 (en) 2001-03-13 2001-03-13 DERIVATIVES OF GLYCINE, N- (N-L-GAMMA-GLUTAMIL-3- (NITROSOTIO) -L-VALIL) AND ITS APPLICATIONS.
PCT/EP2002/002598 WO2002085847A2 (en) 2001-03-13 2002-03-08 Glycine, n-[n-l-gamma-glutamyl-3-(nitrosothio)-l-valyl] and use thereof
AU2002310939A AU2002310939A1 (en) 2001-03-13 2002-03-08 Glycine, n-(n-l-gamma-glutamyl-3-(nitrosothio)-l-valyl) and use thereof
PE2002000189A PE20021040A1 (en) 2001-03-13 2002-03-11 GLYCINE, N- [N-L-g-GLUTAMIL-3- (NITROSOTIO) -L-VALIL] AND ITS APPLICATIONS
PA20028541201A PA8541201A1 (en) 2001-03-13 2002-03-12 GLYCIN, N- [N-L-GAMMA-GLUTAMIL-3- (NITROSOTIO) -L-VALIL] AND ITS APPLICATIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100577A ES2173044B1 (en) 2001-03-13 2001-03-13 DERIVATIVES OF GLYCINE, N- (N-L-GAMMA-GLUTAMIL-3- (NITROSOTIO) -L-VALIL) AND ITS APPLICATIONS.

Publications (2)

Publication Number Publication Date
ES2173044A1 true ES2173044A1 (en) 2002-10-01
ES2173044B1 ES2173044B1 (en) 2004-01-16

Family

ID=8497059

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100577A Expired - Fee Related ES2173044B1 (en) 2001-03-13 2001-03-13 DERIVATIVES OF GLYCINE, N- (N-L-GAMMA-GLUTAMIL-3- (NITROSOTIO) -L-VALIL) AND ITS APPLICATIONS.

Country Status (5)

Country Link
AU (1) AU2002310939A1 (en)
ES (1) ES2173044B1 (en)
PA (1) PA8541201A1 (en)
PE (1) PE20021040A1 (en)
WO (1) WO2002085847A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412699A2 (en) * 1989-08-07 1991-02-13 Takeda Chemical Industries, Ltd. Nitrosothiol derivatives, their production and use
WO2000044714A1 (en) * 1999-01-27 2000-08-03 Lacer, S.A. S-nitrosothiols as agents for the treatment of circulatory dysfunctions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412699A2 (en) * 1989-08-07 1991-02-13 Takeda Chemical Industries, Ltd. Nitrosothiol derivatives, their production and use
WO2000044714A1 (en) * 1999-01-27 2000-08-03 Lacer, S.A. S-nitrosothiols as agents for the treatment of circulatory dysfunctions

Also Published As

Publication number Publication date
PE20021040A1 (en) 2002-11-19
WO2002085847A2 (en) 2002-10-31
AU2002310939A1 (en) 2002-11-05
WO2002085847A3 (en) 2003-10-30
ES2173044B1 (en) 2004-01-16
PA8541201A1 (en) 2003-02-28

Similar Documents

Publication Publication Date Title
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
CA2427227A1 (en) Lactam compound
WO2005056524A3 (en) Therapeutic agents useful for treating pain
WO2004037807A3 (en) Medicinal arylethanolamine compounds
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
TW200503685A (en) A pharmaceutical composition for inhibiting coronavirus
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
SE9901573D0 (en) New compounds
PL1682528T3 (en) BENZO [b][1,4] DIOXEPINE DERIVATIVES
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SE9901572D0 (en) New compounds
ES2173044A1 (en) Glycine, n-[n-l-gamma-glutamyl-3-(nitrosothio)-l-valyl] and use thereof
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
MXPA04005033A (en) Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes.
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20021001

Kind code of ref document: A1

Effective date: 20021001

FG2A Definitive protection

Ref document number: 2173044B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807